A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Travel Medicine and Infectious Disease

Volumn 30, Issue , 2019, Pages 9-18

  Momattin, Hisham ^a   Al Ali, Anfal Y ^b   Al Tawfiq, Jaffar A ^c,d,e  

^a KING KHALID HOSPITAL   (Saudi Arabia)

^b Dhahran Eye Specialist Hospital   (Saudi Arabia)

^c DHAHRAN HEALTH CENTER   (Saudi Arabia)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MERS; Middle east respiratory syndrome coronavirus; Therapy

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CHLOROQUINE; CHLORPROMAZINE; CYCLOPHILIN; CYCLOSPORINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MONOCYTE CHEMOTACTIC PROTEIN 1; NELFINAVIR; NITAZOXANIDE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; REMDESIVIR; RESVERATROL; RIBAVIRIN; RITONAVIR; SARACATINIB; TEICOPLANIN; TOREMIFENE; BETA INTERFERON; LOPINAVIR-RITONAVIR DRUG COMBINATION;

ARTICLE; CALLITHRIX JACCHUS; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDLINE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCIENCEDIRECT; SCOPUS; SYSTEMATIC REVIEW; TREATMENT INDICATION; VIRUS REPLICATION; ANIMAL; CORONAVIRUS INFECTION; DRUG COMBINATION;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; HUMANS; IMMUNOGLOBULIN G; INTERFERON-BETA; LOPINAVIR; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RITONAVIR;

EID: 85068090083     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2019.06.012     Document Type: Article

References (72)

1. Middle, W.H.O., East respiratory syndrome coronavirus (MERS-CoV) - update: 2 DECEMBER 2013 2013. http://www.who.int/csr/don/2013_12_02/en/.
2. Al-Tawfiq, J.A., Auwaerter, P.G., Healthcare-associated infections: the hallmark of the Middle East respiratory syndrome coronavirus (MERS-CoV) with review of the literature. J Hosp Infect, 2018, 10.1016/j.jhin.2018.05.021.
3. Al-Tawfiq, J.A., Memish, Z.A., Drivers of MERS-CoV transmission: what do we know?. Expert Rev Respir Med 10 (2016), 331–338, 10.1586/17476348.2016.1150784.
4. Omrani, A.S., Matin, M.A., Haddad, Q., Al-Nakhli, D., Memish, Z.A., Albarrak, A.M., A family cluster of middle east respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 17 (2013), e668–e672, 10.1016/j.ijid.2013.07.001.
5. Memish, Z.A., Zumla, A.I., Al-Hakeem, R.F., Al-Rabeeah, A a, Stephens, G.M., Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 368 (2013), 2487–2494, 10.1056/NEJMoa1303729.
6. Memish, Z.A., Cotten, M., Watson, S.J., Kellam, P., Zumla, A., Alhakeem, R.F., et al. Community case clusters of Middle East respiratory syndrome coronavirus in hafr Al-batin, kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis 23 (2014), 63–68, 10.1016/j.ijid.2014.03.1372.
7. Drosten, C., Muth, D., Corman, V.M., Hussain, R., Al Masri, M., HajOmar, W., et al. An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia. Clin Infect Dis 60 (2014), 369–377, 10.1093/cid/ciu812 2015.
8. Memish, Z.A., Al-Tawfiq, J.A., Alhakeem, R.F., Assiri, A., Alharby, K.D., Almahallawi, M.S., et al. Middle East respiratory syndrome coronavirus (MERS-CoV): a cluster analysis with implications for global management of suspected cases. Trav Med Infect Dis 13 (2015), 311–314, 10.1016/j.tmaid.2015.06.012.
9. El Bushra, H.E., Abdalla, M.N., Al Arbash, H., Alshayeb, Z., Al-Ali, S., Latif, Z.A.-A., et al. An outbreak of Middle East respiratory syndrome (MERS) due to coronavirus in Al-Ahssa region, Saudi Arabia. East Mediterr Health J 22 (2015), 468–475 2016.
10. Balkhy, H.H., Alenazi, T.H., Alshamrani, M.M., Baffoe-Bonnie, H., Al-Abdely, H.M., El-Saed, A., et al. Notes from the field: nosocomial outbreak of Middle East respiratory syndrome in a large tertiary care hospital–Riyadh, Saudi Arabia. MMWR Morb Mortal Wkly Rep 65 (2015), 163–164, 10.15585/mmwr.mm6506a5 2016.
11. Balkhy, H.H., Alenazi, T.H., Alshamrani, M.M., Baffoe-Bonnie, H., Arabi, Y., Hijazi, R., et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol 37 (2016), 1147–1155, 10.1017/ice.2016.132.
12. Assiri, A.M., Biggs, H.M., Abedi, G.R., Lu, X., Bin Saeed, A., Abdalla, O., et al. Increase in Middle East respiratory syndrome-coronavirus cases in Saudi Arabia linked to hospital outbreak with continued circulation of recombinant virus. Open Forum Infect Dis, 3, 2016, ofw165, 10.1093/ofid/ofw165 July 1-August 31, 2015.
13. Nazer, R.I., Outbreak of Middle East respiratory syndrome-coronavirus causes high fatality after cardiac operations. Ann Thorac Surg 104 (2017), e127–e129, 10.1016/j.athoracsur.2017.02.072.
14. Assiri, A., Abedi, G.R., Bin Saeed, A.A., Abdalla, M.A., al-Masry, M., Choudhry, A.J., et al. Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis 22 (2016), 32–40, 10.3201/eid2201.151370.
15. Hunter, J.C., Nguyen, D., Aden, B., Al Bandar, Z., Al Dhaheri, W., Abu Elkheir, K., et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu dhabi. Emerg Infect Dis 22 (2016), 647–656, 10.3201/eid2204.151615.
16. Cauchemez, S., Van Kerkhove, M.D., Riley, S., Donnelly, C.A., Fraser, C., Ferguson, N.M., Transmission scenarios for middle east respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart. 18, 2013, pii, 20503.
17. Cauchemez, S., Fraser, C., Van Kerkhove, M.D., Donnelly, C.A., Riley, S., Rambaut, A., et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 14 (2014), 50–56, 10.1016/S1473-3099(13)70304-9.
18. Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A.T., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369 (2013), 407–416, 10.1056/NEJMoa1306742.
19. Chowell, G., Abdirizak, F., Lee, S., Lee, J., Jung, E., Nishiura, H., et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med, 13, 2015, 210, 10.1186/s12916-015-0450-0.
20. Al-Abdallat, M.M., Payne, D.C., Alqasrawi, S., Rha, B., Tohme, R.A., Abedi, G.R., et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 59 (2014), 1225–1233, 10.1093/cid/ciu359.
21. Hijawi, B., Abdallat, M., Sayaydeh, A., Alqasrawi, S., Haddadin, A., Jaarour, N., et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 19:Suppl 1 (2013), S12–S18.
22. Oboho, I.K., Tomczyk, S.M., Al-Asmari, A.M., Banjar, A.A., Al-Mugti, H., Aloraini, M.S., et al. MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med 372 (2014), 846–854, 10.1056/NEJMoa1408636 2015.
23. Alraddadi, B., Bawareth, N., Omar, H., Alsalmi, H., Alshukairi, A., Qushmaq, I., et al. Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital. Ann Thorac Med 11 (2016), 128–131, 10.4103/1817-1737.180027.
24. Fagbo, S.F., Skakni, L., Chu, D.K.W., Garbati, M.A., Joseph, M., Peiris, M., et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia. 2015 Emerg Infect Dis, 21, 2014, 10.3201/eid2111.150944 1981–8.
25. Almekhlafi, G.A., Albarrak, M.M., Mandourah, Y., Hassan, S., Alwan, A., Abudayah, A., et al. Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. Crit Care, 20, 2016, 123, 10.1186/s13054-016-1303-8.
26. Saad, M., Omrani, A.S., Baig, K., Bahloul, A., Elzein, F., Matin, M.A., et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29 (2014), 301–306, 10.1016/j.ijid.2014.09.003.
27. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3 (2009), e123–e130.
28. Hart, B.J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R.F., et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 95 (2014), 571–577, 10.1099/vir.0.061911-0.
29. de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens, R.W.A.L., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 94 (2013), 1749–1760, 10.1099/vir.0.052910-0.
30. Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V.J., Feldmann, H., Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep, 3, 2013, 1686, 10.1038/srep01686.
31. Chan, J.F., Chan, K.H., Kao, R.Y., To, K.K., Zheng, B.J., Li, C.P., et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67 (2013), 606–616, 10.1016/j.jinf.2013.09.029.
32. Wu, C.-Y., Jan, J.-T., Ma, S.-H., Kuo, C.-J., Juan, H.-F., Cheng, Y.-S.E., et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci Unit States Am 101 (2004), 10012–10017, 10.1073/pnas.0403596101.
33. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58 (2014), 4875–4884, 10.1128/AAC.03011-14.
34. Shirato, K., Kawase, M., Matsuyama, S., Middle East respiratory syndrome coronavirus (MERS-CoV) infection mediated by the Transmembrane serine protease TMPRSS2. J Virol 87 (2013), 12552–12561, 10.1128/JVI.01890-13.
35. Lu, L., Liu, Q., Zhu, Y., Chan, K.-H., Qin, L., Li, Y., et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun, 5, 2014, 3067, 10.1038/ncomms4067.
36. Shirato, K., Kawase, M., Matsuyama, S., Middle East respiratory syndrome coronavirus infection mediated by the Transmembrane serine protease TMPRSS2. J Virol 87 (2013), 12552–12561, 10.1128/JVI.01890-13.
37. Nitazoxanide, Rossignol J-F., A new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9 (2016), 227–230, 10.1016/j.jiph.2016.04.001.
38. Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., et al. Glycopeptide Antibiotics potently inhibit Cathepsin L in the late Endosome/Lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291 (2016), 9218–9232, 10.1074/jbc.M116.716100.
39. Tai, W., Zhao, G., Sun, S., Guo, Y., Wang, Y., Tao, X., et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499 (2016), 375–382, 10.1016/j.virol.2016.10.005.
40. de Wilde, A.H., Zevenhoven-Dobbe, J.C., van der Meer, Y., Thiel, V., Narayanan, K., Makino, S., et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 92 (2011), 2542–2548, 10.1099/vir.0.034983-0.
41. Cong, Y., Hart, B.J., Gross, R., Zhou, H., Frieman, M., Bollinger, L., et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One, 13, 2018, e0194868, 10.1371/journal.pone.0194868.
42. Dyall, J., Coleman, C.M., Hart, B.J., Venkataraman, T., Holbrook, M.R., Kindrachuk, J., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58 (2014), 4885–4893, 10.1128/AAC.03036-14.
43. Coleman, C.M., Sisk, J.M., Mingo, R.M., Nelson, E.A., White, J.M., Frieman, M.B., Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol 90 (2016), 8924–8933, 10.1128/JVI.01429-16.
44. Shin, J.S., Jung, E., Kim, M., Baric, R.S., Go, Y.Y., Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro. Viruses, 10, 2018, 283, 10.3390/v10060283.
45. Lin, S.-C., Ho, C.-T., Chuo, W.-H., Li, S., Wang, T.T., Lin, C.-C., Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis, 17, 2017, 144, 10.1186/s12879-017-2253-8.
46. Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading Exoribonuclease. mBio, 9, 2018, 10.1128/mBio.00221-18 pii: e00221-18.
47. Lundin, A., Dijkman, R., Bergström, T., Kann, N., Adamiak, B., Hannoun, C., et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. PLoS Pathog, 10, 2014, e1004166, 10.1371/journal.ppat.1004166.
48. Zhao, H., Zhou, J., Zhang, K., Chu, H., Liu, D., Poon, V.K.-M., et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep, 6, 2016, 22008, 10.1038/srep22008.
49. Hindawi, S.I., Hashem, A.M., Damanhouri, G.A., El-Kafrawy, S.A., Tolah, A.M., Hassan, A.M., et al. Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light. Transfusion 58 (2018), 52–59, 10.1111/trf.14422.
50. Johnson, R.F., Bagci, U., Keith, L., Tang, X., Mollura, D.J., Zeitlin, L., et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490 (2016), 49–58, 10.1016/j.virol.2016.01.004.
51. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19 (2013), 1313–1317, 10.1038/nm.3362.
52. Chan, J.F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212 (2015), 1904–1913, 10.1093/infdis/jiv392.
53. Qiu, H., Sun, S., Xiao, H., Feng, J., Guo, Y., Tai, W., et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antivir Res 132 (2016), 141–148, 10.1016/j.antiviral.2016.06.003.
54. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 25 (2015), 1237–1249, 10.1038/cr.2015.113.
55. Channappanavar, R., Lu, L., Xia, S., Du, L., Meyerholz, D.K., Perlman, S., et al. Protective effect of intranasal Regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis 212 (2015), 1894–1903, 10.1093/infdis/jiv325.
56. Zhao, G., He, L., Sun, S., Qiu, H., Tai, W., Chen, J., et al. A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV. J Virol, 92, 2018, 10.1128/JVI.00837-18.
57. Luke, T., Wu, H., Zhao, J., Channappanavar, R., Coleman, C.M., Jiao, J.-A., et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med, 8, 2016, 326ra21, 10.1126/scitranslmed.aaf1061.
58. Tawalah, H., Al-Qabandi, S., Sadiq, M., Chehadeh, C., Al-Hujailan, G., Al-Qaseer, M., The most effective therapeutic regimen for patients with severe Middle East respiratory syndrome coronavirus (MERS-CoV) infection. J Infect Dis Ther 03 (2015), 1–5, 10.4172/2332-0877.1000223.
59. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20 (2014), 42–46, 10.1016/j.ijid.2013.12.003.
60. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14 (2014), 1090–1095, 10.1016/S1473-3099(14)70920-X.
61. Momattin, H., Mohammed, K., Zumla, A., Memish, Z.A., Al-Tawfiq, J.A., Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 17 (2013), e792–e798, 10.1016/j.ijid.2013.07.002.
62. Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 70 (2015), 2129–2132, 10.1093/jac/dkv085.
63. Kim, U.J., Won, E.-J., Kee, S.-J., Jung, S.-I., Jang, H.-C., Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report. Antivir Ther, 2015, 10.3851/IMP3002.
64. Spanakis, N., Tsiodras, S., Haagmans, B.L., Raj, V.S., Pontikis, K., Koutsoukou, A., et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 44 (2014), 528–532, 10.1016/j.ijantimicag.2014.07.026.
65. Khalid, M., Al Rabiah, F., Khan, B., Al Mobeireek, A., Butt, T.S., Al Mutairy, E., Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther 20 (2015), 87–91, 10.3851/IMP2792.
66. Al Ghamdi, M., Alghamdi, K.M., Ghandoora, Y., Alzahrani, A., Salah, F., Alsulami, A., et al. Treatment outcomes for patients with middle Eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the kingdom of Saudi Arabia. BMC Infect Dis, 16, 2016, 174, 10.1186/s12879-016-1492-4.
67. Khalid, M., Khan, B., Al Rabiah, F., Alismaili, R., Saleemi, S., Rehan-Khaliq, A.M., et al. Middle Eastern respiratory syndrome corona virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia. Ann Saudi Med 34 (2014), 396–400, 10.5144/0256-4947.2014.396.
68. Beigel, J.H., Voell, J., Kumar, P., Raviprakash, K., Wu, H., Jiao, J.-A., et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 18 (2018), 410–418, 10.1016/S1473-3099(18)30002-1.
69. Al-Tawfiq, J.A., Memish, Z.A., Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV). Expert Rev Anti Infect Ther 15 (2017), 269–275, 10.1080/14787210.2017.1271712.
70. Arabi, Y.M., Alothman, A., Balkhy, H.H., Al-Dawood, A., AlJohani, S., Al Harbi, S., et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 19, 2018, 81, 10.1186/s13063-017-2427-0.
71. Khalid, I., Alraddadi, B.M., Dairi, Y., Khalid, T.J., Kadri, M., Alshukairi, A.N., et al. Acute management and Long-term survival Among subjects with severe Middle East respiratory syndrome coronavirus pneumonia and ARDS. Respir Care 61 (2016), 340–348, 10.4187/respcare.04325.
72. Malik, A., El Masry, K.M., Ravi, M., Sayed, F., Middle East respiratory syndrome coronavirus during pregnancy, Abu dhabi, United Arab Emirates. Emerg Infect Dis, 22, 2013, 10.3201/eid2203.151049 2016.